KKR Real Estate Finance Trust Inc. (KREF) Earnings
KKR Real Estate Finance Trust Inc. is expected to report next earnings on October 20, 2026 (in NaN days), with a consensus EPS estimate of $-0.26. KREF has beaten EPS estimates in 6 of its last 12 reported quarters (average surprise -118.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 22, 2026 | $-0.56 | $-0.58 | -3.3% | $21M | -16.1% |
| Apr 23, 2026 | $0.15 | $-0.06 | -139.8% | $35M | +23.0% |
| Feb 3, 2026 | $0.13 | $0.22 | +69.2% | $108M | +298.9% |
| Oct 21, 2025 | $0.01 | $-0.03 | -400.0% | $25M | -2.8% |
| Jul 22, 2025 | $-0.16 | $-0.53 | -231.3% | $119M | +267.3% |
| Apr 23, 2025 | $0.17 | $-0.15 | -188.2% | $31M | -11.0% |
| Feb 3, 2025 | $0.08 | $0.31 | +287.5% | $34M | +6.2% |
| Oct 21, 2024 | $0.31 | $0.40 | +29.0% | $37M | +3.8% |
| Jul 22, 2024 | $0.33 | $0.40 | +21.2% | $156M | +326.8% |
| Feb 6, 2024 | $0.45 | $0.47 | +4.4% | $44M | -5.4% |
| Jul 24, 2023 | $0.28 | $0.48 | +71.4% | $44M | -4.5% |
| Feb 7, 2023 | $0.49 | $0.18 | -63.3% | $49M | -4.5% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · July 22, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
### Strategic Review Announcement - The KKR Real Estate Finance Trust (KRF) Board of Directors has launched a review of strategic alternatives to enhance shareholder value, led by an independent director-led strategic review committee. - No transaction proposal has been submitted by KKR to date; KKR will evaluate potential participation as the review proceeds, with no guarantee of a future proposal. KKR, as the largest shareholder, is aligned with the committee's mandate. ### Portfolio Repositioning Progress - Legacy office exposure reduced to 18% of the total portfolio as of Q2 2026, down from 21% at year-end 2025, on track to fall below 10% by the end of 2026. - Watch list assets now represent 16% of the portfolio, with nearly half currently being marketed for sale, targeting full resolution of watch list exposure by year-end 2026. Two watch list loans were resolved during the quarter: one repaid, one transitioned to REO with no material book value impact due to prior reserves. - Life science exposure modifications reached 39% of total life science holdings, up from 19% at the start of 2026. Management expects the vast majority of required reserves have already been recognized, on track to address substantially all life science exposure by year-end 2026. - Originations from 2024-2026 now represent 32% of the portfolio, up from 19% at the start of 2026, building a more resilient portfolio for long-term growth and book value stability. ### Operational Updates - Q2 2026 originations totaled $350 million across 3 loans, with a weighted average LTV of 58%, including a Spanish multifamily portfolio, a Los Angeles multifamily loan, and a California office portfolio loan. European exposure is targeted to remain 20-25% of the total portfolio. - Over $800 million in loan repayments were received in Q2 2026, bringing total 2026 year-to-date repayments to $1.2 billion. REO portfolio progress: entitlement completion expected for the Portland mixed-use project this month; OpenAI will partially occupy the Mountain View asset this quarter with monetization expected within 12 months; first condo sale closed in West Hollywood this month. Philadelphia office REO is currently being marketed for liquidation this year. ### Capital Position and Allocation - End-of-quarter total liquidity exceeded $700 million, with $83 million in cash and $350 million in undrawn corporate revolver capacity; 79% of total financing remains non-mark-to-market. Debt-to-equity ratio was 2.6x, total leverage was 4.3x as of quarter end. - KRF repurchased $38 million of common stock in Q2 2026 at a weighted average price of $6.63 per share, generating ~$0.32 per share of book value accretion; an additional $10 million in repurchases were completed post-quarter end. Future share repurchase decisions will be part of the strategic review process.
Guidance
- Management expects annual distributable earnings before realized losses to cover the $0.40 per year annual dividend, consistent with prior guidance. Earnings are expected to trough in late 2026 and remain near current levels over the next several quarters before portfolio repositioning benefits emerge. - Target leverage range is maintained at 3.5x to 4x total leverage; management expects leverage will naturally decline back into this target range as expected 2026 repayments proceed. - The firm maintains its full-year 2026 forecast of total loan repayments exceeding $2 billion, representing over 35% of the start-of-year portfolio size. - Management expects the most significant book value declines are now behind the firm, and KRF is positioned for greater book value stability going forward. Small incremental fluctuations are possible as asset resolutions finalize.
Segment performance
This transcript does not break out separate financial performance for distinct product segments. All performance data is provided on an aggregated company basis: GAAP net loss of $122 million (-$1.95 per diluted share); distributable loss of $36 million (-$0.58 per diluted share); distributable earnings before realized losses of $6 million ($0.10 per diluted share); book value per share of $10.24 as of June 30, 2026. The overall portfolio is split by asset type as follows: legacy office exposure 18%, watch list assets 16%, post-modification life science exposure 39%, and 2024-2026 vintage new originations 32%.
Risks & headwinds
- Legacy office assets currently face significant market illiquidity, creating uncertainty around clearing valuations for monetization. - Life science leasing demand remains soft overall, particularly in Boston-area markets, meaning certain REO assets will require multi-year timelines to monetize. West Coast life science markets have seen early improvement from AI-related office demand overflow, but the recovery is still in early stages. - Sunbelt multifamily assets face continued pressure from high interest rates and ongoing supply digestion, leading to softness in property values. While management expects no material aggregate losses from the multifamily portfolio, isolated losses and credit downgrades are expected to continue as the market digests supply. - The strategic review process is in early stages, with no guarantee it will result in a value-enhancing transaction, and no further details will be provided until the process advances.
Analyst Q&A
Q: How was this quarter's book value assessment different from prior quarters' reserve builds, and what confidence do you have that book value stability has been reached? /
A: Prior quarters signaled potential further softness as the firm worked through the action plan. This quarter's markdowns reflect updated real-time market feedback from active sale processes that the firm is now conducting for watch list assets. Reserves are now set around current monetization expectations; management notes the most significant book value impact is behind us, with only small potential fluctuations as deals finalize.
Q: What is the update on the non-REO RISC-V Boston life science loan, and what are the broader trends in the life science market? /
A: The firm is in modification discussions for this loan, and it is already fully reserved, so no further negative book value impact is expected. Early green shoots are visible in life science: West Coast markets are seeing more demand improvement, boosted by AI-related tech/office leasing that overlaps with flexible life science/office space, while Boston-area markets are further behind in recovery.
Q: Can stock repurchases continue during the strategic review process, and what is the current ranking of capital allocation priorities? /
A: The strategic review does not preclude share repurchases, but all future capital allocation decisions for buybacks will be reviewed by the strategic committee. Current leverage is above the 3.5-4x target range, so management will wait for expected repayments to bring leverage back into line before resuming new originations, with all decisions aligned with the strategic review process.
Q: What credit trends is management seeing in multifamily, given Sunbelt supply headwinds and high rates? /
A: High-for-longer rates have put additional downward pressure on multifamily values, but management does not expect material aggregate losses from the large multifamily portfolio. Supply digestion is nearly complete, and absorption has been stronger than expected due to high for-sale housing costs; management is optimistic that rents and occupancy will stabilize over the next few quarters.